Safety and feasibility of high-dose administration of nicorandil before reperfusion therapy in acute myocardial infarction

Cardiovascular Intervention and Therapeutics

Volumn 28, Issue 4, 2013, Pages 352-361

  Suematsu, Yasunori ^a,b   Murasato, Yoshinobu ^a   Miura, Shin ichiro ^b   Horiuchi, Masataka ^a,c   Yamamoto, Tomohiko ^a,b   Takata, Kohei ^a,b   Saku, Keijiro ^b  

^a Yukuhashi Clinic   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c Sugimura Hospital   (Japan)

Author keywords

Acute myocardial infarction; Heart failure; Nicorandil

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; HEPARIN; NICORANDIL;

ACUTE HEART INFARCTION; ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; BLOOD PRESSURE; BOLUS INJECTION; BRAIN INFARCTION; CAUSE OF DEATH; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HEART DEATH; HEART MUSCLE REPERFUSION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; INTERSTITIAL PNEUMONIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STENT THROMBOSIS; URINE VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; NICORANDIL; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84885229790     PISSN: 18684300     EISSN: 18684297     Source Type: Journal    
DOI: 10.1007/s12928-013-0182-z     Document Type: Article

References (31)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'infarto Myocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1: 397-402.
2. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (second international study of infarct survival) Collaborative group. Lancet. 1988;2: 349-60.
3. Stone GW, Grines FC, Browne KF, Marco FI, Rothbaum D, O'Keefe FJ, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the primary angioplasty in myocardial infarction (PAMI) trial. J Am Coll Cardiol. 1995;25: 370-7.
4. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervenger JP, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. New Engl J Med. 1999;341: 1413-9.
5. Nakamura M, Yamagishi M, Ueno T, Hara K, Ishiwata S, Itoh T, et al. Current treatment of ST elevation acute myocardial infarction in Japan: door-to-balloon time and total ischemic time from the J-AMI registry. Cardiovasc Interv Ther. 2013;28: 30-6.
6. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Eng J Med. 2007;357: 1121-35.
7. Taira N. Nicorandil as a hybrid between nitrates and potassium cannel activators. Am J Cardiol. 1989;63: 18J-24J.
8. Sanbe A, Marunouchi T, Yamauchi J, Tanonaka K, Nishigori H, Tanoue A. Cardioprotective effect of nicorandil, a mitochondrial ATP-sensitive potassium channel opener, prolongs survival in HSPB5 R120G transgenic mice. PLoS ONE. 2011;4: e18922.
9. Ito H, Taniyama Y, Iwakuma K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999;33: 654-60.
10. Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J. 2004;148: E15.
11. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005;112: 1284-8.
12. Umemura S, Nakamura S, Sugiura T, Tsuka Y, Shimojo M, Baden M, et al. Preservation of myocardial viability within the risk area by intravenous nicorandil before primary coronary intervention in patients with acute myocardial infarction. Nucl Med Commun. 2008;29: 956-62.
13. Kawai Y, Hisamatsu K, Matsubara H, Dan K, Akagi S, Miyaji K, et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. Eur Heart J. 2009;30: 765-72.
14. Iwakura K, Ito H, Okamura A, Koyama Y, Date M, Higuchi Y, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J. 2009;73: 925-31.
15. Ito N, Nanto S, Doi Y, Sawano H, Masuda D, Yamashita S, et al. High index of microcirculatory resistance level after successful primary percutaneous coronary intervention can be improved by intracoronary administration of nicorandil. Circ J. 2010;74: 909-16.
16. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomized trials. Lancet. 2007;370: 1483-93.
17. Tanaka K, Kato K, Takano T, Katagiri T, Asanoi H, Nejima J, et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure. J Cardiol. 2010;56: 291-9.
18. Minami Y, Nagashima M, Kajimoto K, Shiga T, Hagiwara N. Acute efficacy and safety of intravenous administration of nicorandil in patients with acute heart failure syndromes: usefulness of noninvasive echocardiographic hemodynamic evaluation. J Cardiovasc Pharmacol. 2009;54: 335-40.
19. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93: 879-88.
20. Villanueva FS, Glasheen WP, Sklenar J, Kaul S. Characterization of spatial patterns of flow within the reperfused myocardium by myocardial contrast echocardiography. Implications in determining extent of myocardial salvage. Circulation. 1993;88: 2596-606.
21. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93: 223-8.
22. Kotani J, Nanto S, Mintz GS, Kitakaze M, Ohara T, Morozumi T, et al. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation. 2002;106: 1672-7.
23. Ito H. The no-reflow phenomenon associated with percutaneous coronary intervention: its mechanisms and treatment. Cardiovasc Interv Ther. 2011;26: 2-11.
24. Ishii H, Amano T, Matsubara T, Murohara T. Pharmacological intervention for prevention of left ventricular remodeling and improving prognosis in myocardial infarction. Circulation. 2008;118: 2710-8.
25. Ishihara S, Koga T, Kaseda S, Nyuta E, Haga Y, Fujishima S, et al. Effects of intravenous nicorandil on the mid-term prognosis of patients with acute heart failure syndrome. Circ J. 2012;76: 1169-76.
26. Hattori H, Minami Y, Mizuno M, Yumino D, Hoshi H, Arashi H, et al. Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes. Heart Vessels. 2012 (Epub ahead of print).
27. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Hata T, et al. Impact of prodromal angina pectoris and white blood cell count on outcome of patients with acute myocardial infarction. Int J Cardiol. 2005;103: 150-5.
28. Mehta JL, Nichols WW, Mehta P. Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion. J Am Coll Cardiol. 1988;11: 1309-16.
29. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53: 31-47.
30. Engler RL, Schmid-Schönbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol. 1983;111: 98-111.
31. Akai K, Wang Y, Sato K, Sekiguchi N, Sugimura A, Kumagai T, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 1995;26: 541-7.